A Study to Evaluate Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation

Overview

About this study

The overall goal of this study is to develop regenerative cell therapy for use in female patients with aging skin. The primary objective of this proposal is to conduct a pilot study on the efficacy and safety of using platelet rich plasma (PRP) to treat this condition in females.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Only female patients are eligible.
  • Patients must be 45 years of age or older.
  • Patients must have signs of skin aging on face (wrinkles, rough texture, skin atrophy and skin laxity) and hands (loss of fat tissue and visibility of veins and tendons).
  • Patients must have been on stable birth control for the past 6 months if able to conceive
  • Patients are able and willing to provide written informed consent after the study is fully explained.

Exclusion Criteria

  • Patients with clinically abnormal platelet count]\, serum chemistry, or screening laboratory results as reviewed by the Principal Investigator.
  • Patients who have had any cosmetic procedures meant to address skin aging of face and hands 3 months prior to enrollment.
  • Patients who have had resurfacing laser on face or hands within one year prior to enrollment.
  • Patients taking anti-rheumatic disease medication (including methotrexate or other anti-metabolites) within the 3 months prior to study entry.
  • Patients who are pregnant or currently breast-feeding.
  • Patients with systemic, rheumatic, or inflammatory disease or who are immunosuppressed.
  • Patients with ongoing infectious disease, including HIV and hepatitis.
  • Patients with history of significant cardiovascular, renal, hepatic, endocrine disease, cancer, or diabetes.
  • Patients participating in a study of an experimental drug or medical device within 30 days of study entry.
  • Patients with history of platelet disorders, bone marrow aplasia, sepsis, or cancer.
  • Patients taking anti-aggregating therapy.
  • Patients on anticoagulant therapy.
  • Patients with history of keloid formation.
  • Patients with uncontrolled diabetes.
  • Patients with active skin disease or skin infection on the intended treatment areas, at baseline.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Alison Bruce, M.B., Ch.B.

Closed for enrollment

Contact information:

Ena Whitelaw CCRP

Whitelaw.Ena@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20426330

Mayo Clinic Footer